-
Company Insights
NewSilverchain – Digital Transformation Strategies
Silverchain Digital Transformation Strategies Overview Silverchain leverages a real-time, cloud-based Microsoft platform to consolidate real-time patient care information on a single platform. Cloud, virtual care and telemedicine, connected patients, and mixed reality are among the key technologies under focus for the company. The annual ICT spending of Silverchain was estimated at $9.4 million in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. Silverchain leverages a real-time, cloud-based Microsoft...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Smoking Cessation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Smoking Cessation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Smoking Cessation Drug Details: Psilocybin is under investigation for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vidutolimod in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Basal Cell Carcinoma (Basal Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Melanoma Drug Details: RP-1 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Efineptakin Alfa in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efineptakin Alfa in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efineptakin Alfa in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ifinatamab Deruxtecan in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifinatamab Deruxtecan in Squamous Non-Small Cell Lung Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Relatlimab in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Relatlimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Camrelizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Acquired (Autoimmune) Hemolytic Anemia Drug...